ZA200506790B - Arylvinylazacycloalkane compounds and method of preparation and use thereof - Google Patents
Arylvinylazacycloalkane compounds and method of preparation and use thereofInfo
- Publication number
- ZA200506790B ZA200506790B ZA200506790A ZA200506790A ZA200506790B ZA 200506790 B ZA200506790 B ZA 200506790B ZA 200506790 A ZA200506790 A ZA 200506790A ZA 200506790 A ZA200506790 A ZA 200506790A ZA 200506790 B ZA200506790 B ZA 200506790B
- Authority
- ZA
- South Africa
- Prior art keywords
- preparation
- arylvinylazacycloalkane
- compounds
- arylvinylazacycloalkane compounds
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/379,868 US7098331B2 (en) | 2003-03-05 | 2003-03-05 | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200506790B true ZA200506790B (en) | 2006-05-31 |
Family
ID=32926772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200506790A ZA200506790B (en) | 2003-03-05 | 2005-08-24 | Arylvinylazacycloalkane compounds and method of preparation and use thereof |
Country Status (32)
Country | Link |
---|---|
US (8) | US7098331B2 (pl) |
EP (3) | EP2085395B1 (pl) |
JP (3) | JP4663627B2 (pl) |
KR (4) | KR100953150B1 (pl) |
CN (3) | CN100526308C (pl) |
AR (3) | AR043469A1 (pl) |
AT (3) | ATE517893T1 (pl) |
AU (3) | AU2004217903B2 (pl) |
BR (1) | BRPI0409576A (pl) |
CA (1) | CA2516514C (pl) |
CL (1) | CL2004000452A1 (pl) |
CY (2) | CY1110391T1 (pl) |
DE (2) | DE602004031165D1 (pl) |
DK (2) | DK1601670T3 (pl) |
EA (3) | EA019240B1 (pl) |
ES (3) | ES2309507T3 (pl) |
GT (1) | GT200400033A (pl) |
HK (3) | HK1084949A1 (pl) |
IL (3) | IL170155A (pl) |
JO (1) | JO2488B1 (pl) |
MX (1) | MXPA05009386A (pl) |
NO (3) | NO331920B1 (pl) |
NZ (1) | NZ541795A (pl) |
PA (1) | PA8597201A1 (pl) |
PE (1) | PE20040930A1 (pl) |
PL (5) | PL1601670T3 (pl) |
PT (2) | PT1601670E (pl) |
SI (2) | SI1601670T1 (pl) |
TW (3) | TWI339662B (pl) |
UY (1) | UY28218A1 (pl) |
WO (1) | WO2004078752A1 (pl) |
ZA (1) | ZA200506790B (pl) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
FR2896800B1 (fr) * | 2006-01-30 | 2008-04-11 | Servier Lab | Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
WO2008157365A2 (en) * | 2007-06-15 | 2008-12-24 | Targacept, Inc. | Vinylazacycloalkanes for treating neuropathic pain |
EP2296640A1 (en) * | 2008-05-12 | 2011-03-23 | Targacept Inc. | Methods for preventing the development of retinopathy by the oral administration of nnr ligands |
US9145396B2 (en) | 2008-12-01 | 2015-09-29 | Targacept, Inc. | Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine |
TW201024283A (en) * | 2008-12-01 | 2010-07-01 | Targacept Inc | Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine |
RU2533819C2 (ru) * | 2008-12-01 | 2014-11-20 | Таргасепт, Инк. | Синтез и новые солевые формы (r)-5-((e)-2-(пирролидин-3-илвинил)пиримидина |
WO2010080757A2 (en) | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
US20120157477A1 (en) * | 2009-06-17 | 2012-06-21 | Targacept, Inc. | Reversal of l-dopa-induced dyskinesia by neuronal nicotinic receptor ligands |
AU2010328419A1 (en) | 2009-12-07 | 2012-06-21 | Targacept, Inc. | 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands |
CA2792157A1 (en) * | 2010-03-11 | 2011-09-15 | Targacept, Inc. | Arylvinylazacycloalkane compounds for constipation |
US20110274628A1 (en) * | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
US20140081714A1 (en) * | 2012-09-19 | 2014-03-20 | Salesforce.Com, Inc. | Systems and methods of rewarding users in an on-demand system |
US20140278929A1 (en) * | 2013-03-15 | 2014-09-18 | Yahoo! Inc. | System and method identifying opportunities for advertising entities based on user goal achievement |
MX2018012230A (es) | 2016-04-07 | 2019-03-28 | Oyster Point Pharma Inc | Métodos para tratar enfermedades oculares. |
KR101848601B1 (ko) * | 2016-07-27 | 2018-04-12 | 송기봉 | 일회용 위생 티슈 |
EP3820443A1 (en) | 2018-07-10 | 2021-05-19 | Oyster Point Pharma, Inc. | Combinations of positive allosteric modulators and nicotinic acetylcholine receptor agonists for treating ocular conditions |
WO2020014217A1 (en) | 2018-07-10 | 2020-01-16 | Oyster Point Pharma, Inc. | Methods of treating ocular conditions |
WO2021222230A1 (en) | 2020-04-28 | 2021-11-04 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
US4922901A (en) * | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
US5187166A (en) * | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
IT1274018B (it) * | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
US6437138B1 (en) * | 1996-06-06 | 2002-08-20 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
US5629325A (en) | 1996-06-06 | 1997-05-13 | Abbott Laboratories | 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission |
EP1027336B1 (en) | 1997-10-27 | 2004-10-06 | Neurosearch A/S | Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors |
WO2000075110A1 (en) | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
EP1212319A2 (en) | 1999-09-14 | 2002-06-12 | Abbott Laboratories | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
CA2389645A1 (en) | 1999-11-01 | 2001-05-10 | Targacept, Inc. | Aryl olefinic azacyclic, and aryl acetylenic azacyclic compounds, pharmaceutical compositions containing them and their use as inhibitors of nicotinic cholinergic receptors |
US6624167B1 (en) * | 2000-08-04 | 2003-09-23 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6881738B2 (en) | 2001-07-19 | 2005-04-19 | Medical College Of Georgia Research Institute | Analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders |
US7098331B2 (en) * | 2003-03-05 | 2006-08-29 | Targacept, Inc. | Arylvinylazacycloalkane compounds and methods of preparation and use thereof |
-
2003
- 2003-03-05 US US10/379,868 patent/US7098331B2/en not_active Expired - Lifetime
-
2004
- 2004-02-10 TW TW093103017A patent/TWI339662B/zh not_active IP Right Cessation
- 2004-02-10 TW TW098105932A patent/TW200927746A/zh unknown
- 2004-02-10 TW TW098105931A patent/TWI377204B/zh not_active IP Right Cessation
- 2004-03-02 PE PE2004000228A patent/PE20040930A1/es not_active Application Discontinuation
- 2004-03-04 CN CNB2004800060242A patent/CN100526308C/zh not_active Expired - Lifetime
- 2004-03-04 JO JO200422A patent/JO2488B1/en active
- 2004-03-04 AT AT08075106T patent/ATE517893T1/de not_active IP Right Cessation
- 2004-03-04 SI SI200430775T patent/SI1601670T1/sl unknown
- 2004-03-04 PL PL04717398T patent/PL1601670T3/pl unknown
- 2004-03-04 PA PA20048597201A patent/PA8597201A1/es unknown
- 2004-03-04 AU AU2004217903A patent/AU2004217903B2/en not_active Ceased
- 2004-03-04 EA EA200900706A patent/EA019240B1/ru not_active IP Right Cessation
- 2004-03-04 PL PL378415A patent/PL216979B1/pl unknown
- 2004-03-04 EP EP09075124A patent/EP2085395B1/en not_active Expired - Lifetime
- 2004-03-04 BR BRPI0409576-6A patent/BRPI0409576A/pt not_active IP Right Cessation
- 2004-03-04 JP JP2006509059A patent/JP4663627B2/ja not_active Expired - Fee Related
- 2004-03-04 ES ES04717398T patent/ES2309507T3/es not_active Expired - Lifetime
- 2004-03-04 DE DE602004031165T patent/DE602004031165D1/de not_active Expired - Lifetime
- 2004-03-04 PT PT04717398T patent/PT1601670E/pt unknown
- 2004-03-04 PL PL394604A patent/PL215059B1/pl unknown
- 2004-03-04 PL PL394600A patent/PL394600A1/pl unknown
- 2004-03-04 KR KR1020097002099A patent/KR100953150B1/ko not_active IP Right Cessation
- 2004-03-04 CA CA2516514A patent/CA2516514C/en not_active Expired - Lifetime
- 2004-03-04 PT PT09075124T patent/PT2085395E/pt unknown
- 2004-03-04 AT AT09075124T patent/ATE496046T1/de active
- 2004-03-04 KR KR1020127001576A patent/KR20120014236A/ko not_active Application Discontinuation
- 2004-03-04 CN CN2009100048828A patent/CN101550132B/zh not_active Expired - Fee Related
- 2004-03-04 DK DK04717398T patent/DK1601670T3/da active
- 2004-03-04 NZ NZ541795A patent/NZ541795A/en not_active IP Right Cessation
- 2004-03-04 ES ES09075124T patent/ES2385941T3/es not_active Expired - Lifetime
- 2004-03-04 KR KR1020097002098A patent/KR101018083B1/ko not_active IP Right Cessation
- 2004-03-04 UY UY28218A patent/UY28218A1/es not_active Application Discontinuation
- 2004-03-04 ES ES08075106T patent/ES2389106T3/es not_active Expired - Lifetime
- 2004-03-04 DK DK09075124.9T patent/DK2085395T3/da active
- 2004-03-04 PL PL09075124T patent/PL2085395T3/pl unknown
- 2004-03-04 WO PCT/US2004/006530 patent/WO2004078752A1/en active Application Filing
- 2004-03-04 CN CNA2008100917335A patent/CN101255155A/zh active Pending
- 2004-03-04 EP EP04717398A patent/EP1601670B1/en not_active Expired - Lifetime
- 2004-03-04 EP EP08075106A patent/EP1947100B1/en not_active Expired - Lifetime
- 2004-03-04 KR KR1020057016343A patent/KR101185541B1/ko not_active IP Right Cessation
- 2004-03-04 GT GT200400033A patent/GT200400033A/es unknown
- 2004-03-04 SI SI200431638T patent/SI2085395T1/sl unknown
- 2004-03-04 MX MXPA05009386A patent/MXPA05009386A/es active IP Right Grant
- 2004-03-04 EA EA200801764A patent/EA014714B1/ru not_active IP Right Cessation
- 2004-03-04 AR ARP040100690A patent/AR043469A1/es not_active Application Discontinuation
- 2004-03-04 EA EA200501425A patent/EA010870B1/ru active IP Right Revival
- 2004-03-04 DE DE602004013553T patent/DE602004013553D1/de not_active Expired - Lifetime
- 2004-03-04 AT AT04717398T patent/ATE394394T1/de active
- 2004-03-08 CL CL200400452A patent/CL2004000452A1/es unknown
-
2005
- 2005-08-08 IL IL170155A patent/IL170155A/en active IP Right Grant
- 2005-08-17 US US11/206,243 patent/US20060094732A1/en not_active Abandoned
- 2005-08-24 ZA ZA200506790A patent/ZA200506790B/xx unknown
- 2005-09-05 NO NO20054120A patent/NO331920B1/no not_active IP Right Cessation
-
2006
- 2006-05-26 HK HK06106130A patent/HK1084949A1/xx not_active IP Right Cessation
-
2008
- 2008-08-06 CY CY20081100831T patent/CY1110391T1/el unknown
- 2008-08-07 US US12/187,584 patent/US7714001B2/en not_active Expired - Lifetime
- 2008-10-29 HK HK09109159.9A patent/HK1130254A1/xx not_active IP Right Cessation
- 2008-10-29 HK HK08111897.3A patent/HK1116800A1/xx not_active IP Right Cessation
- 2008-12-17 AU AU2008258188A patent/AU2008258188B2/en not_active Ceased
- 2008-12-17 AU AU2008258187A patent/AU2008258187B2/en not_active Ceased
-
2009
- 2009-01-05 US US12/348,605 patent/US8063068B2/en not_active Expired - Lifetime
- 2009-02-05 AR ARP090100389A patent/AR070570A2/es not_active Application Discontinuation
- 2009-02-05 AR ARP090100388A patent/AR070569A2/es not_active Application Discontinuation
- 2009-04-05 IL IL197889A patent/IL197889A/en active IP Right Grant
- 2009-04-05 IL IL197890A patent/IL197890A/en active IP Right Grant
- 2009-05-14 NO NO20091888A patent/NO332293B1/no not_active IP Right Cessation
- 2009-06-09 NO NO20092231A patent/NO20092231L/no unknown
- 2009-07-31 JP JP2009178897A patent/JP5537085B2/ja not_active Expired - Lifetime
- 2009-07-31 JP JP2009178896A patent/JP5537084B2/ja not_active Expired - Lifetime
-
2010
- 2010-01-06 US US12/683,106 patent/US8067443B2/en not_active Expired - Fee Related
-
2011
- 2011-02-24 US US13/033,719 patent/US8633222B2/en not_active Expired - Lifetime
- 2011-04-05 CY CY20111100351T patent/CY1111615T1/el unknown
-
2013
- 2013-12-17 US US14/108,918 patent/US20140107164A1/en not_active Abandoned
-
2015
- 2015-02-24 US US14/629,517 patent/US20150164894A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1116800A1 (en) | Arylvinylazacycloalkane compounds and methods of preparation and use thereof | |
AU2003217870A8 (en) | Pini-modulating compounds and methods of use thereof | |
AU2003213673A8 (en) | Pin1-modulating compounds and methods of use thereof | |
GB0325192D0 (en) | Method of use | |
TWI367766B (en) | Immunoglobulin formulation and method of preparation thereof | |
IL176958A0 (en) | Compounds and methods of use | |
AU2003225669A1 (en) | Pin1-modulating compounds and methods of use thereof | |
AU2003225668A1 (en) | Pin1-modulating compounds and methods of use thereof | |
EP1639086A4 (en) | RNA INTERFERASES AND METHODS OF USE | |
IL169648A0 (en) | Novel structures and method of preparation | |
EP1567515A4 (en) | NEW LAPACHONE COMPOUNDS AND METHODS FOR THE APPLICATION | |
EP1625111A4 (en) | THYRONAMINE DERIVATIVES AND ANALOGUES AND METHODS OF USE THEREOF | |
EP1476150A4 (en) | CARBOXY FULLERES AND USE METHOD THEREFOR | |
IL175657A0 (en) | Derivatives of dihydronepetalactone and method for preparation | |
EP1663255A4 (en) | WITHANAMID AND WITHANOLID COMPOSITIONS AND APPLICATION METHOD THEREFOR | |
EP1678157A4 (en) | Heterocyclic compounds and process for their preparation and use | |
EP1633749A4 (en) | DEAZAFLAVIN COMPOUNDS AND METHODS OF USE | |
EP1625141A4 (en) | GRP94-BASED COMPOSITIONS AND METHODS OF USE THEREOF | |
EP1812451A4 (en) | COMPOUNDS AND METHODS OF USE THEREOF | |
EP1545287A4 (en) | VASOREGULATORY COMPOUNDS AND METHODS RELATING TO THEIR USE | |
AU2003282593A8 (en) | Polyphenolamine composition and method of use | |
GB0304555D0 (en) | Compounds and methods of manufacture | |
EP1686990A4 (en) | 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS: METHODS OF PREPARATION AND USE | |
AU2002333157A1 (en) | Compound for treatment of anxiety and methods of preparation and use thereof | |
EP1591440A4 (en) | ALANINE COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THEIR USE |